kinetic sidebar2


    • FibriComp: Fibrinogen Concentrate is ready to start human clinical trials in 2017

    • A1PI: in lab scale development completed. Ready for human clinical trials in 2018

    • IgG: An IVIG product currently in development with anticipated human clinical trials in 2018

    • ThrombiPlex™ is a Prothrombin Concentrate. Its clinical application will be for patients having ProThrombin deficiency and as a replacement for Fresh Frozen Plasma. This product is ready to start clinical trials in 2017

Other Pipeline Products

    • Factor XI – approved Orphan Drug designation (April 2014)- development in progress

    • Future therapeutics: Fibronectin and Plasminogen

Read About Our Technology

air purification2

Read About Our Latest News


Cambryn Biologics LLC

Cambryn Biologics LLC is a Delaware corporation having its principal facility and offices in Sarasota, Florida. Cambryn is an emerging biotherapeutic company dedicated to the development, manufacturing and commercialization of biologic products for the management and treatment of clotting factor deficiencies.

logo small

State-of-the-Art Manufacturing Facility

Our facility consists of 50,000 square feet, located adjacent to the Sarasota/Bradenton International Airport, Sarasota, Florida, USA. Cambryn Biologics operates a state-of-the-art manufacturing facility.

Contact Details

Address: 600 Tallevast Rd.
Suite 201 Sarasota, FL 34243

Phone: (941) 355-7400

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.